title: FDA approval of doxylamine-pyridoxine therapy for use in pregnancy.
authors.affiliation: From the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
authors.forename: Shelley R
authors.initials: SR
authors.lastname: Slaughter
authors.forename: Rhonda
authors.initials: R
authors.lastname: Hearns-Stokes
authors.forename: Theresa
authors.initials: T
authors.lastname: van der Vlugt
authors.forename: Hylton V
authors.initials: HV
authors.lastname: Joffe
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000013:Congenital Abnormalities; D004025:Dicyclomine / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D004319:Doxylamine / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D017277:Drug Approval / Q000266:history; D004338:Drug Combinations; D005260:Female; D049673:History, 20th Century; D006801:Humans; D048968:Morning Sickness / Q000188:drug therapy*; D011247:Pregnancy; D011736:Pyridoxine / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000932:Antiemetics; D004338:Drug Combinations; C004454:dicyclomine, doxylamine, pyridoxine drug combination; D004025:Dicyclomine; D004319:Doxylamine; D011736:Pyridoxine